Bookmark

Add to MyYahoo RSS

Isis Pharmaceuticals News

News on Isis Pharmaceuticals (Ticker: ISIS) continually updated from thousands of sources around the net.

Yesterday | Freshnews

Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call

What: Isis Pharmaceuticals' Second Quarter 2014 Financial Results and Highlights Conference Call When: Monday, August 4 at 10:30 a.m. ET /7:30 a.m. PT Where: www.isispharm.com How: Live on the Internet.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Sun Jul 20, 2014

The Motley Fool

ISIS Pharmaceuticals, Inc. is The Best Stock Today

The Motley Fool's Better Stock Today tournament has declared a winner! Among the 32 companies pitted against each other our reader's voices your voice were heard loud and clear : Isis Pharmaceuticals is the best stock today.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Wed Jul 16, 2014

Applied Clinical Trials

Isis Pharmaceuticals Earns $1 Million from GSK for Advancing ISIS-TTR Rx

ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, GlaxoSmithKline, Genetics, Marketing

Fri Jul 11, 2014

AmericanBankingNews.com

Isis Pharmaceuticals Inc 1,800 Shares of Regulus Therapeutics Stock

Regulus Therapeutics Director Isis Pharmaceuticals Inc 1,800 shares of the company's stock in a transaction that occurred on Wednesday, July 9th.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Wed Jul 02, 2014

BioSpace

Isis Pharmaceuticals, Inc. Earns $1 Million From GlaxoSmithKline For...

"Our collaboration with GSK has been very productive resulting in three novel antisense drugs in our pipeline.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, GlaxoSmithKline, Hepatitis, Health, Liver Cancer

Contract Pharma Breaking News

Isis Earns GSK Milestone

Isis Pharmaceuticals, Inc. has earned a $1 million payment from GlaxoSmithKline for the advancement of its development program for antisense drugs to treat hepatitis B virus .

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, GlaxoSmithKline, Hepatitis, Health

•••
•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••